Seed Innovations Limited Investee Company Update: Eurox Group
January 12 2022 - 3:15AM
RNS Non-Regulatory
TIDMSEED
Seed Innovations Limited
12 January 2022
Seed Innovations Ltd / AIM: SEED / Sector: Closed End
Investments
12 January 2022
SEED Innovations Limited ("SEED" or the "Company")
Investee Company Update: Eurox Group
SEED Innovations Ltd, the AIM quoted company investing in fast
growing and industry leading businesses with a focus on the medical
cannabis, health and wellness space, is pleased to provide an
update on its portfolio company Eurox Group ("Eurox"), a
German-based, European vertically integrated medical cannabis
company.
SEED is pleased to note that following a non-exclusive marketing
and distribution agreement entered into between Eurox and AMP
Alternative Medical Products GmbH ("AMP"), a wholly owned
subsidiary of Greenrise Global Brands Inc., AMP are beginning the
sale of Dronabinol produced by Eurox in Germany , with the aim for
Dronabinol to be ready for sale in pharmacies beginning in February
2022.
SEED has an 8.85% shareholding in Eurox.
Highlights:
-- Dronabinol is already a well-established product in Germany;
it is pure Tetrahydrocannabinol (THC) and is registered as an
active pharmaceutical ingredient (API) for sale by approved
authorities in Germany
-- AMP and Eurox entered into a non-exclusive marketing and
distribution agreement for Dronabinol for sale in pharmacies
beginning in February 2022
-- Eurox was one of the first medical cannabis companies to
produce Dronabinol that is 'Made in Germany', at one of Europe's
largest GMP facilities located in Hessen, Germany
-- Eurox controls the entire supply chain from cultivation,
production to distribution ensuring the highest quality of product
as well as guaranteeing stable and efficient supply to its
customers
Ed McDermott, CEO of SEED, commented: " The latest announcement
with AMP strengthens the position of Eurox as one of Europe's
leading medical cannabis companies and allows further access to the
German pharmaceutical and health market for Eurox's 'Made in
Germany' products. Myself and the team at Seed are excited to
continue our support and see further growth within the medical
cannabis sector."
About Eurox Group
Eurox is a German-based, European vertically integrated medical
cannabis company with:
-- Fully owned German subsidiaries responsible for product development & holding IP.
-- EU GMP manufacturing in Germany together with a German pharmaceutical partner.
-- A cultivation facility in Portugal to secure vertical integration and supply independence.
-- A significant minority ownership of Integro Medical Clinics,
a UK registered medical cannabis clinic.
-- Various high caliber distribution partnerships in Germany and
other European countries & its own sales team.
For more information on Eurox, visit https://www.eurox-pharma.com
***ENDS***
For further information on the Company please visit
www.seedinnovations.co or contact:
Ed McDermott SEED Innovations E: info@seedinnovations.co
Lance de Jersey Ltd
James Biddle Beaumont Cornish T: (0)20 7628 3396
Roland Cornish Limited,
Nomad
----------------------- -------------------------------
Isabella Pierre Shard Capital Partners T: (0)20 7186 9927
Damon Heath LLP
Broker
----------------------- -------------------------------
Catherine Leftley St Brides Partners E: info@stbridespartners.co.uk
Isabelle Morris Ltd,
Financial PR
----------------------- -------------------------------
Notes
SEED Innovations is an AIM quoted investment company focused
primarily on disruptive high growth life sciences and technology
businesses particularly within the medical cannabis arena. The
Company's strategy is to identify early-stage opportunities that
have an upcoming investment catalyst and grow its portfolio in
terms of value whilst limiting the number of investee companies to
a level where relevant time can be devoted to each.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGCGDBBBBDGDD
(END) Dow Jones Newswires
January 12, 2022 04:15 ET (09:15 GMT)
Fastforward Innovations (LSE:FFWD)
Historical Stock Chart
From Apr 2024 to May 2024
Fastforward Innovations (LSE:FFWD)
Historical Stock Chart
From May 2023 to May 2024